![Clinical Conundrums: Choosing the Best Management Approaches in Patients With Ovarian Cancer Thomas J. Herzog, MD Director, Division of Gynecologic Oncology. - ppt download Clinical Conundrums: Choosing the Best Management Approaches in Patients With Ovarian Cancer Thomas J. Herzog, MD Director, Division of Gynecologic Oncology. - ppt download](https://slideplayer.com/slide/6837466/23/images/62/AGO-OVAR+DESKTOP+III+%28Protocol+AGO-+OVAR+OP.4%29.jpg)
Clinical Conundrums: Choosing the Best Management Approaches in Patients With Ovarian Cancer Thomas J. Herzog, MD Director, Division of Gynecologic Oncology. - ppt download
Dr. STEFANY CARDOSO FARIA - MÉDICO ONCOLOGISTA: #ASCO 2017 Randomized controlled phase III study evaluating the impact of secondary cytoreductive surgery in recurrent ovarian cancer: AGO DESKTOP III/ENGOT ov20
![Frontiers | Prediction Models for Complete Resection in Secondary Cytoreductive Surgery of Patients With Recurrent Ovarian Cancer Frontiers | Prediction Models for Complete Resection in Secondary Cytoreductive Surgery of Patients With Recurrent Ovarian Cancer](https://www.frontiersin.org/files/Articles/674637/fonc-11-674637-HTML/image_m/fonc-11-674637-t001.jpg)
Frontiers | Prediction Models for Complete Resection in Secondary Cytoreductive Surgery of Patients With Recurrent Ovarian Cancer
![Study Comparing Tumor Debulking Surgery Versus Chemotherapy Alone in Recurrent Platinum-Sensitive Ovarian Cancer Study Comparing Tumor Debulking Surgery Versus Chemotherapy Alone in Recurrent Platinum-Sensitive Ovarian Cancer](https://larvolclin.s3.us-west-2.amazonaws.com/resize_163803327540913426961a2677b1bf3b.jpg)
Study Comparing Tumor Debulking Surgery Versus Chemotherapy Alone in Recurrent Platinum-Sensitive Ovarian Cancer
![Study Comparing Tumor Debulking Surgery Versus Chemotherapy Alone in Recurrent Platinum-Sensitive Ovarian Cancer Study Comparing Tumor Debulking Surgery Versus Chemotherapy Alone in Recurrent Platinum-Sensitive Ovarian Cancer](https://larvolclin.s3.us-west-2.amazonaws.com/resize_1638033299154495691161a26793670f1.jpg)
Study Comparing Tumor Debulking Surgery Versus Chemotherapy Alone in Recurrent Platinum-Sensitive Ovarian Cancer
![Fumiko Ladd Chino, MD Twitter'da: "🚨@Oncoalert: Dr Helen MacKay summarizes #gyncsm highlights including Desktop III (compared to Soc-1 and GOG-213) for recurrent epithelial #ovariancancer showing a 7.7 month OS benefit from 2ndary Fumiko Ladd Chino, MD Twitter'da: "🚨@Oncoalert: Dr Helen MacKay summarizes #gyncsm highlights including Desktop III (compared to Soc-1 and GOG-213) for recurrent epithelial #ovariancancer showing a 7.7 month OS benefit from 2ndary](https://pbs.twimg.com/media/EZSq8XHXkAAVLo9.jpg)
Fumiko Ladd Chino, MD Twitter'da: "🚨@Oncoalert: Dr Helen MacKay summarizes #gyncsm highlights including Desktop III (compared to Soc-1 and GOG-213) for recurrent epithelial #ovariancancer showing a 7.7 month OS benefit from 2ndary
![توییتر \ Shannon Westin در توییتر: «DESKTOP III demonstrated improved PFS and OS for patients that underwent surgery for recurrent #ovariancancer #ASCO20 #SGOatASCO #gyncsm https://t.co/z0dEmwPzOk» توییتر \ Shannon Westin در توییتر: «DESKTOP III demonstrated improved PFS and OS for patients that underwent surgery for recurrent #ovariancancer #ASCO20 #SGOatASCO #gyncsm https://t.co/z0dEmwPzOk»](https://pbs.twimg.com/media/EZSnPKNWoAExnUV.jpg)
توییتر \ Shannon Westin در توییتر: «DESKTOP III demonstrated improved PFS and OS for patients that underwent surgery for recurrent #ovariancancer #ASCO20 #SGOatASCO #gyncsm https://t.co/z0dEmwPzOk»
![Mauricio Lema-Medina on Twitter: "#esmo17 -DESKTOP III: Only potential R0 resection (<500 mL ascites, Good PS, Optimal 1ry debulking) should undergo 2ry cytoreduction in OvCa https://t.co/WP7uHBw4pr" / Twitter Mauricio Lema-Medina on Twitter: "#esmo17 -DESKTOP III: Only potential R0 resection (<500 mL ascites, Good PS, Optimal 1ry debulking) should undergo 2ry cytoreduction in OvCa https://t.co/WP7uHBw4pr" / Twitter](https://pbs.twimg.com/media/DJSY-lSXUAAUS2v.jpg)
Mauricio Lema-Medina on Twitter: "#esmo17 -DESKTOP III: Only potential R0 resection (<500 mL ascites, Good PS, Optimal 1ry debulking) should undergo 2ry cytoreduction in OvCa https://t.co/WP7uHBw4pr" / Twitter
![توییتر \ Shannon Westin در توییتر: «DESKTOP III demonstrated improved PFS and OS for patients that underwent surgery for recurrent #ovariancancer #ASCO20 #SGOatASCO #gyncsm https://t.co/z0dEmwPzOk» توییتر \ Shannon Westin در توییتر: «DESKTOP III demonstrated improved PFS and OS for patients that underwent surgery for recurrent #ovariancancer #ASCO20 #SGOatASCO #gyncsm https://t.co/z0dEmwPzOk»](https://pbs.twimg.com/media/EZSmC5NXQAIuBCf.jpg)
توییتر \ Shannon Westin در توییتر: «DESKTOP III demonstrated improved PFS and OS for patients that underwent surgery for recurrent #ovariancancer #ASCO20 #SGOatASCO #gyncsm https://t.co/z0dEmwPzOk»
![توییتر \ Shannon Westin در توییتر: «DESKTOP III demonstrated improved PFS and OS for patients that underwent surgery for recurrent #ovariancancer #ASCO20 #SGOatASCO #gyncsm https://t.co/z0dEmwPzOk» توییتر \ Shannon Westin در توییتر: «DESKTOP III demonstrated improved PFS and OS for patients that underwent surgery for recurrent #ovariancancer #ASCO20 #SGOatASCO #gyncsm https://t.co/z0dEmwPzOk»](https://pbs.twimg.com/media/EZSjjnKWoAEysTp.jpg)